Drospirenone-containing oral contraceptive pills and the risk of venous and arterial thrombosis: A systematic review

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 120, Issue 7, 2013, Pages 801-811

  Wu, C Q ^a,b   Grandi, S M ^b   Filion, K B ^b,c   Abenhaim, H A ^b,d   Joseph, L ^c,e   Eisenberg, M J ^b,d  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d MCGILL UNIVERSITY   (Canada)

^e MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

Arterial thrombosis; deep vein thrombosis; drospirenone; myocardial infarction; oral contraceptive pills; pulmonary embolism; venous thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; CARDIOLIPIN ANTIBODY; DESOGESTREL; DROSPIRENONE; ETHINYLESTRADIOL; IMMUNOGLOBULIN G; LEVONORGESTREL; NORGESTIMATE; ORAL CONTRACEPTIVE AGENT; PROTHROMBIN;

ARTERY THROMBOSIS; ARTICLE; CEREBROVASCULAR ACCIDENT; DIABETES MELLITUS; FAMILY HISTORY; GENE MUTATION; GENETIC PREDISPOSITION; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMOBILIZATION; INCIDENCE; OBESITY; PRIORITY JOURNAL; RISK ASSESSMENT; SMOKING; SYSTEMATIC REVIEW; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

EID: 84877747094     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/1471-0528.12210     Document Type: Article

References (41)

1. Tchaikovski SN, Rosing J,. Mechanisms of estrogen-induced venous thromboembolism. Thromb Res 2010; 126: 5-11.
2. Tanis BC, van den Bosch MA, Kemmeren JM, Cats VM, Helmerhorst FM, Algra A, et al. Oral contraceptives and the risk of myocardial infarction. N Engl J Med 2001; 345: 1787-93.
3. Vandenbroucke JP, Rosing J, Bloemenkamp KW, Middeldrop S, Helmerhorst FM, Bouma BM, et al. Oral contraceptives and the risk of venous thrombosis. N Engl J Med 2001; 344: 1527-35.
4. Petitti DB,. Combination estrogen-progestin oral contraceptives. N Engl J Med 2003; 349: 1443-50.
5. Orti G, Mira Y, Vaya A,. Acute myocardial infarction associated with Yasmin oral contraceptive. Clin Appl Thromb Hemost 2007; 13: 336-7.
6. Mishell DR Jr,. YAZ and the novel progestin drospirenone. J Reprod Med 2008; 53: 721-8.
7. Parkin L, Sharples K, Hernandez RK, Jick SS,. Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database. Br Med J 2011; 342: d1239.
8. Jick SS, Hernandez RK,. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data. Br Med J 2011; 342: d2151.
9. Dinger J, Assmann A, Mohner S, Minh TD,. Risk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: results from a German case-control study. J Fam Plann Reprod Health Care 2010; 36: 123-9.
10. FDA Advisory Committee Joint Meeting: Reproductive Health Drugs; Drug Safety and Risk Management. 2011 [www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/ UCM284784.pdf]. Accessed 12 January 2012.
11. FDA Drug Safety Communication: Updated information about the FDA-funded study on risk of blood clots in women taking birth control pills containing drospirenone. 2011 [www.fda.gov/Drugs/DrugSafety/ucm299305.htm]. Accessed 30 December 2011.
12. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. J Am Med Assoc 2000; 283: 2008-12.
13. Moher D, Liberati A, Tetzlaff J, Altman DG,. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009; 151: W64.
14. Van Grootheest K, Vrieling T,. Drug points: thromboembolism associated with the new contraceptive Yasmin. Br Med J 2003; 326: 257.
15. Lopez M, Vaya A, Martinez Triguero ML, Contreras MT, Todolí J, Ricart A, et al. Yasmin and venous thromboembolism: new case reports. Clin Hemorheol Microcirc 2009; 42: 65-9.
16. Oo TH,. Deep vein thrombosis associated with the new oral contraceptive Yasmin. South Med J 2009; 102: 985-6.
17. Pearce HM, Layton D, Wilton LV, Shakir SAW,. Deep vein thrombosis and pulmonary embolism reported in the Prescription Event Monitoring Study of Yasmin. Br J Clin Pharmacol 2005; 60: 98-102.
18. Marti Gil C, Mulet Alberola A, Mejia Recuero M, Barreira Hernandez D, Llopis Salvia P, Barreda Hernandez D,. Update on combined oral contraceptives: risk of venous thromboembolism. Drospirenone versus other progestins. Eur J Hosp Pharm 2012; 19: 254.
19. Cabou C, Lacroix I, Roncalli J, Elbaz M, Caillaux D, Damase-Michel C, et al. Myocardial infarction in a young female smoker taking oral contraception. Infarctus du myocarde chez une jeune femme fumeuse sous contraception orale. Arch Mal Coeur Vaiss 2006; 99: 80-5.
20. Zehir R, Karabay CY, Kocabay G,. Myocardial infarction and spontaneous dissection of coronary artery due to oral contraceptive. J Cardiovasc Med 2011; 12: 448-50.
21. Vaya A, Mira Y, Ferrando F, Aznar J, Garcia-Fuster Ma J,. Transient ischaemic attack associated with the new contraceptive Yasmin. Thromb Res 2004; 112: 121.
22. Lidegaard O, Nielsen LH, Skovlund CW, Skjeldestad FE, Lokkegaard E,. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. Br Med J 2011; 343: d6423.
23. Gronich N, Lavi I, Rennert G,. Higher risk of venous thrombosis associated with drospirenone-containing oral contraceptives: a population-based cohort study. Can Med Assoc J 2011; 183: E1319-25.
24. Dinger JC, Heinemann LA, Kuhl-Habich D,. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception 2007; 75: 344-54.
25. Lidegaard O, Lokkegaard E, Svendsen AL, Agger C,. Hormonal contraception and risk of venous thromboembolism: national follow-up study. Br Med J 2009; 339: b2890.
26. Seeger JD, Loughlin J, Eng PM, Clifford CR, Cutone J, Walker AM,. Risk of thromboembolism in women taking ethinylestradiol/drospirenone and other oral contraceptives. Obstet Gynecol 2007; 110: 587-93.
27. Leppee M, Culig J,. Difference between drospirenone-containing oral contraceptives and other oral contraceptives related to risk of venous thromboembolism. J Fam Plann Reprod Health Care 2012; 38: 137-8.
28. Vlieg AV, Helmerhorst FM, Vandenbroucke JP, Doggen CJM, Rosendaal FR,. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. Br Med J 2009; 339: b2921.
29. Lidegaard O, Lokkegaard E, Jensen A, Skovlund CW, Keiding N,. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med 2012; 366: 2257-66.
30. Suissa S,. The Transnational study of oral contraceptive cardiovascular safety: history and science. J Clin Epidemiol 2009; 62: 588-93.
31. Suissa S, Blais L, Spitzer WO, Cusson J, Lewis M, Heinemann L,. First-time use of newer oral contraceptives and the risk of venous thromboembolism. Contraception 1997; 56: 141-6.
32. Ray WA,. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003; 158: 915-20.
33. Sorensen HT, Horvath-Puho E, Pedersen L, Baron JA, Prandoni P,. Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular events: a 20-year cohort study. Lancet 2007; 370: 1773-9.
34. Yasmin: risk of venous thromboembolism higher than levonorgestrel- containing pills. 2011 [www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/ CON120214]. Accessed 30 December 2011.
35. Yasmin and Yaz (drospirenone): Updated information on increased risk of blood clots. 2011 [www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/-2011/2011-164- eng.php]. Accessed 30 December 2011.
36. FDA Drug Safety Communication: Updated information about the risk of blood clots in women taking birth control pills containing drospirenone. 2012 [www.fda.gov/Drugs/DrugSafety/ucm299305.htm]. Accessed 14 May 2012.
37. Manzoli L, De Vito C, Marzuillo C, Boccia A, Villari P,. Oral contraceptives and venous thromboembolism: a systematic review and meta-analysis. Drug Saf 2012; 35: 191-205.
38. Martinez F, Ramirez I, Perez-Campos E, Latorre K, Lete I,. Venous and pulmonary thromboembolism and combined hormonal contraceptives. Systematic review and meta-analysis. Eur J Contracept Reprod Health Care 2012; 17: 7-29.
39. Lidegaard O,. The influence of thrombotic risk factors when oral contraceptives are prescribed. A control-only study. Acta Obstet Gynecol Scand 1997; 76: 252-60.
40. Heinemann LA, Dinger J,. Safety of a new oral contraceptive containing drospirenone. Drug Saf 2004; 27: 1001-18.
41. Dinger J, Shapiro S,. Combined oral contraceptives, venous thromboembolism, and the problem of interpreting large but incomplete datasets. J Fam Plann Reprod Health Care 2012; 38: 2-6.